Although its exact mechanism in the treatment of partial-onset seizures is unknown, cenobamate has been shown to reduce repetitive neuronal firing by inhibiting voltage-gated sodium currents. The Food ...

Research Triangle Park, NC (January 20, 2002) – GlaxoSmithKline announced today that the U.S. Food and Drug Administration (FDA) granted marketing clearance for Lamictal® (lamotrigine) Tablets as ...

Partial seizures are the most common seizure type in children. New antiepileptic drugs are needed because current treatments are often inadequate, or have intolerable adverse effects. Levetiracetam ...

Boston, MA, May 1, 2007 -- Data from two clinical trials presented today at the American Academy of Neurology (AAN) meeting suggest that an investigational once daily extended release formulation of ...

Treatment approved for patients whose seizures are still uncontrolled with first adjunctive therapy The All Wales Medicines Strategy Group (AWMSG) has issued a Final Appraisal Recommendation (FAR) on ...

SK Life Science has announced the availability of Xcopri (cenobamate) tablets for the treatment of partial-onset seizures in adults.  SK Life Science has announced the availability of Xcopri ...

BRUSSELS, BELGIUM--(MARKET WIRE)--Oct 29, 2008 -- Brussels, BELGIUM, October 29, 2008 at 7:00 CET- press release, regulated information - UCB announced today that the U.S. Food and Drug Administration ...

Seizures can affect your daily life and well-being. Certain medicines can help lower the risk of having seizures, which can help manage your condition. Fycompa is a medicine used to manage ...

child yellow pill medicine Safety data for Fycompa was consistent with the safety profile in adult populations without the need for weight-based dosing. The Food and Drug Administration has expanded ...

Imagine yourself at one of the coolest, wildest parties ever. I’m talking about one of those loud, crazy, intense parties where whatever could happen, does happen, and there’s just so much stimulation ...

Vertex Announces Completion of Phase 2 Study of VX-765 in People with Epilepsy who did not Respond to Previous Treatment -Results support continued development of VX-765 in people with ...